-
After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
Global pharmaceutical giant Pfizer may be considering selling its hospital drug division. Foreign media reported this week that Pfizer is seeking to sell its hospital drug division to divest non core ... -
Pfizer plans to sell hospital drug division, company responds
Pfizer responded to Interface News on November 14th, stating, "We do not comment on the recent rumors and debunking emails regarding the sale of business units Previously, according to reports citing ... -
Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
The 7th China International Import Expo (CIIE) has come to an end, attracting dozens of Fortune 500 original pharmaceutical companies to gather in the medical device and healthcare exhibition area, w ... -
Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
On November 5th, the opening day of the 7th CIIE, Pfizer announced that its innovative drug, Terazopanib Tosylate Capsules (trade name: Taizena), has recently been approved for market by the National ... -
Pfizer's innovative targeted therapy drug Taizena has been approved in China
The reporter learned that Pfizer's innovative drug for treating prostate cancer, Terzena& reg; （TALZENNA®， The generic name: Terazopanib Tosylate Capsules was approved by the National Medical P ... -
Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
On November 2nd, it was learned from Pfizer that during the 7th China International Import Expo, Pfizer will showcase 24 globally leading innovative products and solutions under the theme of "Pfizer ... -
Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
Pfizer's official WeChat account announced on October 25th that the 2024 International Biomedical Industry Innovation Beijing Forum officially opened on the afternoon of October 24th. At the meeting, ... -
The first weekly long-acting hemophilia therapy has been approved by the FDA from Pfizer
On October 11th local time, the US FDA approved Pfizer's drug Hympavzi (marstalimab) for routine prevention or reduction of bleeding in adult and pediatric patients aged 12 and above with hemophilia ... -
Pfizer CEO may meet with key executives of radical investor Starboard Value next week
On October 8th, sources familiar with the matter said that Pfizer CEO Abel plans to meet with key executives of radical investor Starboard Value next week. Previously, it was reported that Starboard ... -
Pfizer and Shangyao Holdings have reached a strategic cooperation to jointly create a new format of high-quality preventive immunization services
On September 26th, Pfizer Investment Co., Ltd. (Pfizer) and Shangyao Holdings Co., Ltd. (Shangyao Holdings) signed a strategic cooperation framework agreement. The two parties will focus on the vacci ... -
The Phase II clinical trial of Pfizer Ponsegromab in the treatment of cancer cachexia has reached its primary endpoint
On September 22, Pfizer announced on its official WeChat account that its phase II clinical trial of the monoclonal antibody Ponsegromab targeting growth differentiation factor-15 (GDF-15) had reache ... -
Pfizer launches drug sales platform directly targeting American patients
On August 27, PfizerForAll.com, a user friendly platform launched by Pfizer, allows American users to make an appointment for vaccination or have a virtual meeting with doctors, who can prescribe dru ... -
The number of infected cases has surged! US FDA approves Pfizer and Modena's updated COVID-19 vaccine
[A surge of infection cases! The US FDA approved the updated COVID-19 vaccine of Pfizer and Modena] On Thursday, the US Food and Drug Administration (FDA) approved the new COVID-19 vaccine of Pfizer ... -
Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
On August 13th, the official website of the Drug Evaluation Center (CDE) of the China National Medical Products Administration (NMPA) announced that the Class 1 therapeutic biological product Mataxim ... -
Pfizer's Q2 2024 revenue of $13.3 billion
Pfizer announced its performance on July 30th, with Q2 2024 revenue of $13.3 billion. Pfizer expects its annual revenue to be between $59.5 billion and $62.5 billion, with an estimated adjusted earni ... -
Pfizer fights cancer business again, plans to expand these territories in China within six years
Pfizer, which had a revenue of more than 100 billion US dollars, is now targeting the tumor field as it seeks new growth points in its performance after COVID-19's business dividend has declined. The ... -
Pfizer invests $743 million to expand its Singapore factory
Pfizer announced on the website of the Singapore Economic Development Board on July 23 that it has invested SGD 1 billion (USD 743 million) to expand its automated production facility for active phar ... -
Pfizer Chief Scientist to step down
Pfizer announced on July 9th that the company is initiating the process of determining a successor for Mikael Dolsten, Pfizer's Chief Scientist and President of Global Research and Medicine. This pro ... -
France has received a total investment commitment of 15 billion euros from companies such as Microsoft, Amazon, and Pfizer
On May 14th, it was reported that during this year's "Choose France" investment summit, France received a total investment commitment of 15 billion euros (approximately 16.16 billion US dollars) from ... -
Pfizer plans to launch a drug platform directly targeting consumers
Pfizer plans to launch a direct consumer drug platform. On May 13th, Pfizer plans to place the Pfizer for All brand on a direct consumer drug platform. According to a document from the US Patent and ...